SCHEMBL5204510

SCHEMBL5204510

CC(NC(=O)C1CCC(CNC(=O)OCc2ccccc2)CC1)C(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.48
ATM Q13315 2/20 0.45
CCR2 P41597 3/20 0.43
CCR3 P51677 1/20 0.43
MEN1 O00255 2/20 0.42
CYP3A4 P08684 5/20 0.42
CYP1A2 P05177 3/20 0.42
CYP2D6 P10635 3/20 0.42
CYP2C9 P11712 3/20 0.42
CYP2C19 P33261 2/20 0.42
TSHR P16473 2/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
PLG P00747 1/20 0.41
PRSS1 P07477 1/20 0.41
PRSS2 P07478 1/20 0.41
PRSS3 P35030 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14608977 1.00 KMT2A (0.48) KMT2AATMCCR2CCR3MEN1
SCHEMBL14608979 0.84 CCR2 (0.45) CCR2CCR3ALDH1A1LMNAKCNH2
SCHEMBL5202821 0.84 CCR2 (0.45) CCR2CCR3ALDH1A1LMNAKCNH2
SCHEMBL7258424 0.80 CCR2 (0.43) KMT2ACCR2CCR3MEN1CYP3A4
SCHEMBL5202827 0.75 MGLL (0.40) KMT2ACCR2CCR3MEN1CYP3A4
SCHEMBL3484242 0.74 CTSK (0.48) KMT2AATMMEN1LMNA
SCHEMBL12190794 0.74 CTSK (0.48) KMT2AATMMEN1LMNA
SCHEMBL1060083 0.74 CTSK (0.48) KMT2AATMMEN1LMNA
SCHEMBL6475959 0.73 HTT (0.48) KMT2AMEN1CYP3A4CYP1A2CYP2D6
SCHEMBL8393648 0.72 LMNA (0.58) KMT2AMEN1CYP3A4CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1306085-B1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor NEUROGEN CORP (US) 2007-02-14 EP disclosed
US-7034034-B2 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION (US) 2006-04-25 US disclosed
US-20030144290-A1 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION 2003-07-31 US disclosed
EP-1306085-A1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor Neurogen Corporation (US) 2003-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144290-A1 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NPY5R, NPY4R, NPY1R KMT2A 2283/4885ATM 4413/4885CCR2 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.